Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Key trials in bladder cancer from ASCO GU 2022

Guru Sonpavde • 18 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Enfortumab vedotin
EV-103

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, discusses some of the key trial data presented at ASCO GU 2022, including the EV-103 trial on enfortumab vedotin for muscle invasive bladder cancer (NCT03288545), as well as the potential of PARP inhibitors in this field. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Guru Sonpavde

How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
0:39
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
Guru Sonpavde • 24 Oct 2026
EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer
1:20
EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer
Guru Sonpavde • 24 Oct 2026
KEYNOTE-905/EV-303: perioperative EV and pembrolizumab in MIBC
2:33
KEYNOTE-905/EV-303: perioperative EV and pembrolizumab in MIBC
Guru Sonpavde • 19 Oct 2025

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals